OncoMatch/Clinical Trials/NCT04147078
Personalized DC Vaccine for Postoperative Cancer
Is NCT04147078 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DC vaccine subcutaneous administration for gastric cancer.
Treatment: DC vaccine subcutaneous administration — The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
adequate organ functions
Kidney function
adequate organ functions
Liver function
adequate organ functions
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04147078 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages